Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13841156 | 0.90 | MEN1 (0.46) | GRM5MEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL31510723 | 0.84 | GRM5 (0.41) | GRM5MEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL20014800 | 0.83 | GRM5 (0.50) | GRM5MEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL3926927 | 0.82 | NPC1 (0.44) | GRM5MEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL6688964 | 0.81 | GRM5 (0.57) | GRM5MEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL212404 | 0.81 | RORC (0.37) | MEN1KMT2ARAB9ARORCHPGD | |
| SCHEMBL30273556 | 0.80 | MEN1 (0.43) | GRM5MEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL8240830 | 0.80 | HPGD (0.41) | SMN1; SMN2L3MBTL1GAAHPGDSIGMAR1 | |
| SCHEMBL22476355 | 0.80 | LMNA (0.40) | SMN1; SMN2PTGDR2 | |
| SCHEMBL23123262 | 0.79 | PKM (0.36) | GRM5MEN1KMT2ACYP2C19RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117185987-A | Amidine and guanidine derivatives, preparation method and medical application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-111630048-B | Amidine and guanidine derivatives, preparation method and medical application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230035133-A1 | [1,2,4]Triazolo[4,3-B]Pyridazines For Use in the Treatment of Proliferative Diseases | ASTRAZENECA AB (SE) | 2023-02-02 | — | — | US | disclosed |
| US-20230035133-A1 | [1,2,4]Triazolo[4,3-B]Pyridazines For Use in the Treatment of Proliferative Diseases | ASTRAZENECA AB (SE) | 2023-02-02 | — | — | US | disclosed |
| US-11407755-B2 | [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2022-08-09 | — | — | US | disclosed |
| US-20210107905-A1 | 1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2021-04-15 | — | — | US | disclosed |
| US-20210107905-A1 | 1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2021-04-15 | — | — | US | disclosed |
| US-10766905-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2020-09-08 | — | — | US | disclosed |
| US-10766905-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2020-09-08 | — | — | US | disclosed |
| US-20200055861-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA UK LIMITED (GB) | 2020-02-20 | — | — | US | disclosed |
| US-20040220171-A1 | 1-Aroyl-piperidinyl benzamidines | AVENTIS PHARMACEUTICALS INC | 2004-11-04 | — | — | US | disclosed |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2004-02-12 | — | — | US | disclosed |
| US-20030232836-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-18 | — | — | US | disclosed |
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-11 | — | — | US | disclosed |
| US-20030187020-A1 | Chemical compounds | AVENTISUB LLC | 2003-10-02 | — | — | US | disclosed |
| EP-1296972-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| EP-1278732-A1 | 1-AROYL-PIPERIDINYL BENZAMIDINES | Aventis Pharmaceuticals Inc. (US) | 2003-01-29 | — | — | EP | disclosed |
| US-20020045613-A1 | 1-aroyl-piperidinyl benzamidines | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2002-04-18 | — | — | US | disclosed |
| WO-2001090101-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001081310-A1 | 1-AROYL-PIPERIDINYL BENZAMIDINES | AVENTIS PHARMACEUTICALS INC. (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | GRM5 1577/4885MEN1 2828/4885KMT2A 2169/4885 |
| US-20040220171-A1 | 1-Aroyl-piperidinyl benzamidines | TPSAB1, TPSB2, CMA1 | GRM5 3203/4885MEN1 489/4885KMT2A 2080/4885 |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | GRM5 1577/4885MEN1 2828/4885KMT2A 2169/4885 |
| US-20200055861-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | MKI67, CCNB1, CCNB2 | GRM5 3828/4885MEN1 619/4885KMT2A 2735/4885 |
| US-20210107905-A1 | 1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | MKI67, CCNB1, BCL2 | GRM5 3878/4885MEN1 794/4885KMT2A 2678/4885 |
| US-20020045613-A1 | 1-aroyl-piperidinyl benzamidines | TPSAB1, TPSB2, CMA1 | GRM5 3203/4885MEN1 489/4885KMT2A 2080/4885 |
| US-11407755-B2 | [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases | MKI67, CCNB1, CCNB2 | GRM5 3828/4885MEN1 619/4885KMT2A 2735/4885 |
| US-20030187020-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | GRM5 1797/4885MEN1 2733/4885KMT2A 2305/4885 |
| US-20230035133-A1 | [1,2,4]Triazolo[4,3-B]Pyridazines For Use in the Treatment of Proliferative Diseases | MKI67, CCNB1, CCNB2 | GRM5 3828/4885MEN1 619/4885KMT2A 2735/4885 |
| US-20030232836-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | GRM5 1577/4885MEN1 2828/4885KMT2A 2169/4885 |
| US-10766905-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | MKI67, CCNB1, CCNB2 | GRM5 3828/4885MEN1 619/4885KMT2A 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.